EMA agrees on ''black triangle'' for new drugs launched in EU
This article was originally published in Scrip
Executive Summary
All new products launched in the EU will have to display a black inverted triangle on their product information denoting that the product is subject to additional monitoring, if the European Commission accepts the advice of the new pharmacovigilance committee (PRAC) at the European Medicines Agency.